In multiple myeloma cells, pomalidomide and lenalidomide induce the breakdown of Ikaros (IKZF1) and Aiolos (IKZF3), resulting in IRF4 downregulation and cell growth defects7–9. Here, IKZF1 is linked to plasma cell myeloma.